Intellia Therapeutics Inc Sustainability Reports
Intellia Therapeutics, Inc. is a clinical-stage genome editing company focused on developing curative therapeutics using the CRISPR/Cas9 system. The company designs both in vivo treatments delivered directly to target tissues and ex vivo therapies using engineered human cells.
Sector: Professional & technical services
Country: United States
Exchange: Nasdaq
ISIN: US45826J1051
9 reports from 2018 to 2026